Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{186128,
        author = {KEERTHANA H and VIGNESH A and DHARANI PRIYA S M and SHAMIKSHA  R and BIBIN CHANDRU S A},
        title = {Herbal Bioactive Compounds as Emerging Therapeutics in Non-Alcoholic Fatty Liver Disease: A Comprehensive Review},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {12},
        number = {6},
        pages = {500-514},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=186128},
        abstract = {non-alcoholic fatty liver disease (NAFLD), recently redefined as metabolic dysfunction–associated steatotic liver disease (MASLD), is now the most common chronic liver disorder worldwide, strongly linked with obesity, diabetes, dyslipidemia, and hypertension. Its pathogenesis follows the “multiple-hit” hypothesis, involving insulin resistance, lipotoxicity, oxidative stress, inflammation, gut dysbiosis, and genetic predisposition. Progression ranges from simple steatosis to nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma, with fibrosis being the key predictor of outcomes. Diagnosis integrates laboratory markers, imaging techniques, non-invasive scoring systems, and, in selected cases, liver biopsy. With no FDA-approved drugs, lifestyle modification remains the primary treatment. Increasing evidence highlights nutraceuticals and bioactive compounds—such as curcumin, silymarin, resveratrol, omega-3 fatty acids, quercetin, and coenzyme Q10—for their antioxidant, anti-inflammatory, and lipid-modulating effects. Clinical and preclinical studies demonstrate improvements in liver enzymes, steatosis, and fibrosis, suggesting these agents as promising complementary therapies.},
        keywords = {Curcumin; Herbal bioactive compounds; Metabolic dysfunction–associated steatotic liver disease (MASLD); Metabolic syndrome; Non-alcoholic fatty liver disease (NAFLD); Nutraceuticals; Omega-3 fatty acids; Quercetin; Resveratrol; Silymarin.},
        month = {November},
        }